GlaxoSmithKline Agrees to Pay $90 Million to Settle Illegal Promotion of Avandia Claims
- Ennis & Ennis
11/16/2012 - GlaxoSmithKline (GSK) has agreed to pay $90 million to settle claims filed by state attorney generals in 38 states for illegally marketing the diabetes drug, Avandia. The lawsuits allege GSK misrepresented Avandia’s safety and misled consumers about whether the drug caused heart attack, stroke and congestive heart failure in order to skyrocket sales.
Avandia lawsuits are no surprise to GSK. In July 2012 GSK agreed to the largest-ever U.S. settlement involving healthcare fraud, paying $3 billion to settle criminal and civil claims that it failed to provide regulators with information regarding the risk of heart attack, stroke and congestive heart failure associated with Avandia.
Unfortunately these settlements of the criminal claims come a little too late for those who have suffered cardiac events as a result of Avandia and are now subjects of pending civil claims. In fact, looking at a timeline of Avandia events calls to question the trust that consumers can have in big pharma companies like GSK.
In 1999, the FDA approved Avandia for regulating blood sugar in people with diabetes. In 2001 GSK begins a six-ear study (RECORD) of Avandia and later reports that the study showed no heart risks. In June 2007 , Dr. Steven Nissen, chief cardiologist at the Cleveland Clinic, published in the New England Journal of Medicine his analysis of Avandia clinical trials, stating that Avandia increases the risk of heart attack by 43 percent. In December 2007, after reviewing Dr. Nissen’s analysis, the FDA required a stronger warning label on Avandia warning of the risk of heart failure. In November 2008 Archives of Internal Medicine publishes a study revealing that Avandia patients were 15% more likely to die and 13% more likely to suffer congestive heart failure than patients taking competitor diabetes drug, Actos. In February 2010, the Senate Finance Committee accuses GSK of knowing of the cardiac risk and hiding the related data to promote sales. In June 2010, The Journal of American Medicine Association and the Archives of Internal Medicine publish separate studies concluding Avandia should be taken off the market.
Denying the adverse cardiac events caused by Avandia was simply a delay tactic by GSK so that it could continue to generate Avandia sales. Considering the deceit, these settlement amounts are a drop in the bucket for GSK when Avandia, formerly a blockbuster drug for GSK, generated $2.5 billion in annual sales in 2006 alone.
Avandia Side Effects Lawsuit News Archive::
If you or a loved one have experienced an Avandia heart attack, Avandia stroke, Avandia congestive heart failure, Avandia cardiovascular disease or if you have lost a loved one to an Avandia death you may be entitled to compensation. Contact the Avandia attorneys of Ennis & Ennis today for a free confidential case evaluation. Our on staff nurse and lawyers are standing by to answer any questions you may have regarding Avandia, Avandamet or Rosiglitazone side effects, a possible Avandia class action lawsuit, or any other type of Avandia litigation. Fill out the free Avandia case evaluation form on this page or call us toll-free at: 1.800.856.6405.
Under no circumstances should you discontinue taking any medication, including Avandia without first consulting with your doctor